2023 · Oral Presentation · Yes · Methods/Pharmacoepi
ICPE
Resources and insights tagged icpe from Headwater.
Publications
18
Total Publications
18
Oral Presentation
2023 · Oral Presentation · Yes · Methods/Pharmacoepi
Characterizing the Distribution of Multiple Negative Control Outcome Risk Differences
Read more →2023 · Oral Presentation · Yes · Methods/Pharmacoepi
Orthogonalized Regression for Causal Inference: A Pharmacoepidemiologist's Dream?
Read more →2023 · Oral Presentation · Yes · Methods/Pharmacoepi
An Analytic Method to Weight Longitudinal Treatment Patterns for Visualization with Sankey Diagrams
Read more →2022 · Oral Presentation · Yes · Methods/Pharmacoepi
In-Hospital Treatment Patterns Among Patients Hospitalized with COVID-19 in the United States
Read more →2022 · Oral Presentation · Yes · Methods/Pharmacoepi
Discharged Where? The Importance of Understanding Discharge Dispositions When Estimating In-Hospital Mortality
Read more →2022 · Oral Presentation · Amgen Inc. · Methods/Pharmacoepi
Fracture Risk Estimation in Post-menopausal Women: A Comparison of Machine Learning Methods and Software Systems
Read more →2022 · Oral Presentation · Yes · Methods/Pharmacoepi
Risk Factors for Mortality and Intensive Care Requirements Among Pediatric Patients Hospitalized with COVID-19 in the United States
Read more →2022 · Oral Presentation · Yes · Methods/Pharmacoepi
The Effect of Remdesivir for The Treatment of COVID-19 on Mortality Among Hospitalized Patients
Read more →2022 · Oral Presentation · No · Methods/Pharmacoepi
One Design to Rule Them All: The Clone-Censor-Weight Design as a General Framework for Epidemiologic Studies
Read more →2022 · Oral Presentation · Yes · Methods/Pharmacoepi
Negative Control Outcomes to Assess the Comparability of Biologics versus Small-molecule Therapeutics for Osteoporosis: Considerations for Differential Non-adherence
Read more →2022 · Oral Presentation · Yes · Methods/Pharmacoepi
The impact of parametric assumptions on the bias-variance tradeoff for causal analysis of time-to-event outcomes
Read more →2021 · Oral Presentation · No · Methods/Pharmacoepi
Use of negative control outcomes to detect mismeasured confounders in administrative data
Read more →2020 · Oral Presentation · No · Methods/Pharmacoepi
Real world treatment patterns following the initiation of proprotein convertase subtilisin/kexin type 9 antibody inhibitors among adults in the United States, 2015-2019
Read more →2020 · Oral Presentation · No · Methods/Pharmacoepi
History of lipid lowering therapy use among adults initiating treatment with proprotein convertase subtilisin/kexin type 9 antibody inhibitors in the United States, 2015-2019
Read more →2018 · Oral Presentation · No · Methods/Pharmacoepi
Performance of machine learning algorithms for hysterectomy risk prediction among women with endometriosis in the United States
Read more →2018 · Oral Presentation · University of North Carolina at Chapel Hill · Methods/Pharmacoepi
Agreement between electronic health records and administrative claims data for patients with multiple myeloma
Read more →2018 · Oral Presentation · University of North Carolina at Chapel Hill · Methods/Pharmacoepi
Using Negative Control Outcomes to Assess the Comparability of Osteoporosis Treatment Groups
Read more →Latest News
Contact us
By submitting this form, you consent to your information used by Headwater Science for the purpose of contacting you to better understand your potential interest in Headwater Science and/or its services. For more information, see our privacy policy.
Pedestal Health projects leverage Headwater Science methods, technology and causal inference expertise where the analytical complexity is highest, comparative effectiveness studies that require dynamic treatment design, regulatory-grade external control work, methodological consultation on submission packages, and the kinds of bias-protection frameworks that consequential evidence increasingly requires.
Pedestal Health projects leverage Headwater Science methods, technology and causal inference expertise where the analytical complexity is highest, comparative effectiveness studies that require dynamic treatment design, regulatory-grade external control work, methodological consultation on submission packages, and the kinds of bias-protection frameworks that consequential evidence increasingly requires.